Aminex Therapeutics, Inc., is a drug development company exclusively focused on development and clinical efficacy of a unique cancer immunotherapy drug in the general category of cancer immunomodulators.  Aminex’s novel cancer immunotherapy drug, AMXT 1501/DFMO, engages, in multiple animal trials, the immune system to attack and clear cancer primary tumors and its metastases.  AMXT 1501/DFMO negates two major immune system suppressors--polyamines and myeloid-derived suppressor cells (MDSCs). Further, it compromises the cancer-driving roles of both the MYC and RAS oncogenes, thought to be involved with more than sixty percent of solid tumors. DFMO itself is a special drug separately as a component of neuroblastoma standard of care and of research interest in colorectal cancer prevention, glioblastoma and Alzheimer’s. AMXT 1501 has been specifically developed to enhance and extend, in conjunction with DFMO, the ability of the immune system to recognize and attack multiple cancers.


Aminex has operated with private funding in tranches totaling $10 million since its founding. These funds have enabled all drug development and FDA preclinical requirements for AMXT 1501/DFMO human clinical trials. The final preclinical task, submittal of an Independent New Drug (IND) application to the FDA, is scheduled for March 2018. A planned Series B round of up to $10 million to fund the remainder of the Phase 1/2A human clinical trials will be initiated at that time.


Aminex has made few scientific presentations and is currently "under the radar".  That will change soon with an IND submittal,  clinical trial initiation and a planned peer-reviewed publication.


An extensive array of animal data supports the likelihood that AMXT 1501/DFMO should be effective in human cancer clinical trials. Initial signals of efficacy in cancer patients with solid tumors could be observed as early as the fall of 2018. Our vision is for AMXT 1501/DFMO to be a foundational and transformational drug therapy, for use alone and in combination with other immunotherapy treatments. AMXT 1501/DFMO’s small molecule design and low chemical production costs will allow substantial pricing flexibility compared to the pricing of current biologics and cell therapy treatments. Aminex believes AMXT 1501/DFMO will be of major benefit for mankind.